Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of
progression-free survival at 6 months in patients with platinum resistant advanced ovarian
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Investigación en Cáncer de Ovario